Publications by authors named "W Chemlali"

Claim this Profile
R
Response to mTOR and PI3K inhibitors in enzalutamide-resistant luminal androgen receptor triple-negative breast cancer patient-derived xenografts.
Florence Coussy, Marion Lavigne, Leanne de Koning, Rania El Botty, Fariba Nemati, Walid Chemlali

Theranostics· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Molecular features of untreated breast cancer and initial metastatic event inform clinical decision-making and predict outcome: long-term results of ESOPE, a single-arm prospective multicenter study.
Céline Callens, Keltouma Driouch, Anaïs Boulai, Zakia Tariq, Aurélie Comte, Walid Chemlali

Genome Med· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Genomic Instability Signature of Palindromic Non-Coding Somatic Mutations in Bladder Cancer.
Sophie Vacher, Voreak Suybeng, Elodie Girard, Julien Masliah Planchon, Grégory Thomson, Walid Chemlali

Cancers (Basel)· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Biopathological Significance of PIWI-piRNA Pathway Deregulation in Invasive Breast Carcinomas.
Didier Meseure, Sophie Vacher, Sabah Boudjemaa, Marick Laé, André Nicolas, Walid Chemlali

Cancers (Basel)· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PLK1 inhibition exhibits strong anti-tumoral activity in CCND1-driven breast cancer metastases with acquired palbociclib resistance.
Elodie Montaudon, Joanna Nikitorowicz-Buniak, Laura Sourd, Ludivine Morisset, Rania El Botty, Walid Chemlali

Nat Commun· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis